Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Lancet; 1998 Sep 12;352(9131):854-65. PMID: 9742977
Category:
You are here
Home » Tags » metformin
metformin
Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians.
Qaseem, Amir; Humphrey, Linda L; Sweet, Donna E; Starkey, Melissa; Shekelle, Paul
Annals of internal medicine; 2012 Feb 7;156(3):218-31. PMID: 22312141
Category:
Whose Diabetes Treatment Recommendations are Correct?
Posted March 8, 2012 by Irl B. Hirsch, MDTags:
Primary care physicians are expected to be experts on dozens of different disease states despite the fact that each medical problem continues to evolve, with new understanding of the disease itself and its treatments. Frankly, I see this as a near impossible task since as an endocrinologist I can barely keep up with diabetes (in reality I can’t).
Tailoring Clinical Practice Guidelines for Patients with Type 2 Diabetes
Posted September 21, 2011 by Sonal Singh, MD, MPHSeveral guidelines emphasize the need to use existing therapeutic options to help patients and providers achieve various treatment goals, including target glycated hemoglobin levels to improve microvascular outcomes among patients with type 2 diabetes. 1 Blood pressure medications and lipid lowering therapy and prophylactic aspirin therapy are recommended to improve cardiovascular outcomes. Influenza and pneumococcal vaccination strategies are recommended to reduce the risk of subsequent infections.
Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations.
Bennett, Wendy L; Maruthur, Nisa M; Singh, Sonal; Segal, Jodi B; Wilson, Lisa M; Chatterjee, Ranee; Marinopoulos, Spyridon S; Puhan, Milo A; Ranasinghe, Padmini; Block, Lauren; Nicholson, Wanda K; Hutfless, Susan; Bass, Eric B; Bolen, Shari
Annals of internal medicine; 2011 May 3;154(9):602-13. PMID: 21403054
Category:
Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT.
Kahn, Steven E; Lachin, John M; Zinman, Bernard; Haffner, Steven M; Aftring, R Paul; Paul, Gitanjali; Kravitz, Barbara G; Herman, William H; Viberti, Giancarlo; Holman, Rury R
Diabetes; 2011 May;60(5):1552-60. PMID: 21415383
Category:
Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention).
Gerstein, Hertzel; Yusuf, Salim; Riddle, Matthew C; Ryden, Lars; Bosch, Jackie
American heart journal; 2008 Jan;155(1):26-32, 32.e1-6. PMID: 18082485
Category:
Can Current Drug Therapy Prevent Beta Cell Failure and Bring Treatment Durability in T2DM?
Posted July 20, 2011 by John L. Leahy, MDTags:
A hot topic in the type 2 diabetes world is whether we have in hand the tools to stop the decline in beta cell function that typifies this disease and, consequently, a therapy or therapies that successfully control blood glucose for many years – so-called treatment durability. Actually this is three topics. What are the specific mechanisms for the beta cell failure? Do any of our existing therapies, or those on the drawing board, reverse these mechanisms to slow or stop the beta cell failure?
Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis.
Gross, Jorge L; Kramer, Caroline K; Leitão, Cristiane B; Hawkins, Neil; Viana, Luciana V; Schaan, Beatriz D; Pinto, Lana C; Rodrigues, Ticiana C; Azevedo, Mirela J
Annals of internal medicine; 2011 May 17;154(10):672-9. PMID: 21576535
Category:
T2DM and Fatty Liver Disease: Is What’s Good for the Gander Good for the Goose?
Posted April 7, 2011 by Kim C. Dixon, MDTags:
Fatty liver disease is the most common cause of chronic liver disease in North America[1] and is becoming one of the top reasons for liver transplantation. Fatty liver causes inflammation that can lead to fibrosis, cirrhosis, and hepatocellular carcinoma. The physiologic relationship between type 2 diabetes mellitus and fatty liver disease is complex and multifactorial.